CN1198625C - 用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物 - Google Patents

用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物 Download PDF

Info

Publication number
CN1198625C
CN1198625C CNB018134386A CN01813438A CN1198625C CN 1198625 C CN1198625 C CN 1198625C CN B018134386 A CNB018134386 A CN B018134386A CN 01813438 A CN01813438 A CN 01813438A CN 1198625 C CN1198625 C CN 1198625C
Authority
CN
China
Prior art keywords
treatment
compositions
sodium
mucositis
enoxolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018134386A
Other languages
English (en)
Other versions
CN1474700A (zh
Inventor
M·马斯特罗多纳托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Pharmaceutical Co Ltd
Original Assignee
Sinclair Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair Pharmaceuticals Ltd filed Critical Sinclair Pharmaceuticals Ltd
Publication of CN1474700A publication Critical patent/CN1474700A/zh
Application granted granted Critical
Publication of CN1198625C publication Critical patent/CN1198625C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明涉及一种用于治疗湿润上皮表面的疼痛、炎症和溃疡状况如粘膜炎和贝赫切特综合征的、含有有效剂量的透明质酸、甘草次酸和聚乙烯吡咯烷酮作为活性成分的药物组合物。

Description

用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物
本发明涉及用于治疗湿润表面(包括口、口咽、食管、阴道和直肠)的疼痛性溃疡和炎症(包括但不仅限于粘膜炎、口炎、贝赫切特综合征)的含有透明质酸、甘草次酸和聚乙烯吡咯烷酮的药物组合物。
发明背景
术语粘膜炎和口炎常常可以互换使用,但可以包括一些一般的区别。粘膜炎描述了影响胃肠道的毒性炎症反应,它可以是由于接触了化疗剂或电离辐射而引起的。粘膜炎的典型表现为红斑、烧伤样损伤或随机的、从集中到扩散的溃疡性损伤。
口炎指的是影响口腔粘膜的炎症反应,可以出现或不出现溃疡,其可以是由于药理学治疗、特别是化疗或由于放疗而引起或加重的。口炎的程度可以从轻微到严重;遭受严重口炎的患者不能用嘴来摄取任何东西。
许多妇女在月经周期的特定时间会出现口腔的口疮性溃疡并同时在生殖道上,特别是外阴和阴道上出现相同的溃疡。这种情况有时十分严重,能造成尿潴留,并且需要强效的止痛剂和镇静剂。最严重的形式被称为贝赫切特综合征。
在下面的描述中,更为概况的术语粘膜炎也用来表示口炎。对粘膜炎的研究证明了该作用并支持了权利要求。
在进行化疗或放疗后早至三天,就可能会出现红斑性粘膜炎,但是一般在五至七天内出现。一般在开始化疗后七天内会发展成溃疡性粘膜炎,这种粘膜炎有时可以达到非常严重的程度,以至于需要停止该药理学治疗。粘膜炎可以涉及口腔和口咽以及从口腔到肛门的胃肠道。我们在这里将该体验限制在易于接近的区域如口腔、口咽、食管和直肠的粘膜炎。
因为在接受化疗的患者中出现各种程度的粘膜炎的百分比很高(从30至40%),所以十分需要一种方便有效的治疗。到目前为止,实际上并不能获得有效的治疗,人们一直在试图通过用止痛剂、抗菌剂和口腔保健措施或减轻症状来解决这一问题。
此外,因为粘膜炎常常发生于HIV患者、特别是伴有卡波济氏肉瘤的患者,而且还常常发生于患有非何杰金氏淋巴瘤的患者、虚弱的中老年患者和接受BRM治疗如白介素-2、TNF、干扰素、淋巴因子激活的淋巴细胞等的患者,所以粘膜炎的问题并不仅限于癌症患者。
本发明的公开
已经令人吃惊的发现将含有透明质酸、甘草次酸和聚乙烯吡咯烷酮的药物制剂局部给药对于各种起因和严重程度的粘膜炎和口炎能提供有效的治疗和预防性处理,更一般的讲,能有效的预防和治疗口-咽腔和食管的损伤,特别是那些由于牙科器械和放疗或化疗而造成的损伤。
因此,本发明第一方面提供了一种包含有效剂量的透明质酸、甘草次酸和聚乙烯吡咯烷酮作为活性成分的药物组合物,这些活性成分与赋形剂和辅剂相混合,形成能持续粘附在表面上皮上的、适于对上皮表面例如但不仅限于口咽和食管局部给药的粘的且润滑的物质。
本发明另一方面涉及透明质酸、甘草次酸和聚乙烯吡咯烷酮在制备用于局部治疗上皮表面(例如但不仅限于口腔粘膜)的炎症状态、特别是粘膜炎和口炎的药物中的应用。
本发明的详细公开
本发明的组合物是能在上皮表面(例如但不仅限于口腔粘膜)提供成膜和覆盖效果的微粘的水溶液(凝胶)形式。
透明质酸以0.01至约5%,优选约0.1%的重量百分比存在。透明质酸还可以以钠盐的形式存在,优选通过生物技术获得的,分子量为1.6至2.2106Da的透明质酸。
聚乙烯吡咯烷酮或聚维酮(PVP)是一种广泛用于制药技术的混悬剂和粘合剂。其以1至20%重量,优选5至10%的重量百分比存在于本发明的制剂中。
甘草次酸可以以0.01至3%重量的重量百分比存在。
优选地使用高分子量的聚维酮,例如K-30至K-120的聚维酮,优选具有约1,000,000的平均分子量的聚维酮K-90。
本发明的组合物还含有适于局部给药的赋形剂,如:
-增粘剂;
-表面活性剂;
-稳定剂-防腐剂;
-矫味剂、芳香剂、甜味剂;
-生物胶粘剂;
-共溶剂。
所说赋形剂的实例包括纤维素衍生物、丙烯酸或甲基丙烯酸聚合物或共聚物、乙二醇或丙二醇、聚乙氧基化氢化蓖麻油、EDTA、苯甲酸钠、山梨酸钠或山梨酸钾、糊精、糖精钠、阿司帕坦和在漱口剂或液体口服形式的制剂中常用的其它赋形剂。
本发明的组合物还可以进一步包含具有互补作用或任何有用活性的其它活性成分,如抗菌剂/消毒剂、杀真菌剂、止痛剂、抗炎剂、柔润剂、局部麻醉剂等等。适宜的抗菌剂包括季铵盐如苯扎氯铵。
最后,本发明的组合物可以以单剂量或多剂量的形式存在,例如小药囊、小瓶、安瓿、瓶等等。
剂量取决于大量的因素,如所治疗疾病的严重程度、类型和蔓延情况:但是,原则上,可用经水稀释或未经稀释的1-50ml溶液清洗或含漱两或三分钟,每天三次或更多次,优选在饭前使用,这样就足以提供最佳的治疗或预防效果。该治疗可延续至症状缓解,通常需进行5-10天。考虑到即使有毒性的话,本发明制剂中组分的毒性也极低,所以更长期的治疗并不禁忌。
通过使用本发明的制剂所获得的良好治疗效果是由于透明质酸、甘草次酸和聚乙烯吡咯烷酮之间的协同作用,并且该制剂能粘附到口腔粘膜上的能力还为所暴露的神经末梢提供了保护性的覆盖层,因此能减少疼痛并能促进该损伤的愈合和恢复。此外,该组合物的润湿作用也是有益的,因其能保护粘膜免受进一步的刺激损伤。
将用下面的实施例对本发明进行更详细的解释。
实施例1
定性定量组合物百分比组成
透明质酸钠                                  0.1
甘草次酸                                    0.06
PVP                                         9.0
麦芽糖糊精                                  6.00
丙二醇                                      2.94
山梨酸钾                                    0.3
苯甲酸钠                                    0.3
羟乙基纤维素                                1.5
氢化蓖麻油PEG-40                            0.27
EDTA二钠                                    0.1
苯扎氯铵                                    0.5
香料(Glycyrrhiza Comp.2717)                 0.16
糖精钠                                      0.1
净化水                                      78.44
对于其制备而言,先将水放置在涡轮式乳化器中,然后将山梨酸钾、苯甲酸钠和EDTA二钠的混合物加入到其中,然后再加入透明质酸和麦芽糖糊精。在加入各物质后将该混合物进行搅拌直至这些组分完全溶解。在此之后,在搅拌和真空(30mmHg)条件下,缓慢加入PVP直至其完全溶解。然后将糖精钠和羟乙基纤维素依次加入到其中,将所有组分置于真空下并将其进行搅拌直至其完全溶解。然后,将氢化蓖麻油40/OE和香料、苯扎氯铵、以及丙二醇和甘草次酸按该顺序加入到其中,在加入各组分后对其进行搅拌直至这些组分完全溶解。当加入所有的组分后,将该混合物在真空下搅拌30分钟。
对于本发明浓缩的形式而言,将10ml或15ml如上所述的组合物分装于小袋或单剂量小瓶中,在使用前用30-50ml的水进行稀释;对于本发明的即可使用的形式而言,将上述组合物用净化水稀释至50%的浓度,并以200ml或300ml的量装瓶。
实施例2
临床试验
用30名年龄在30至60岁之间的患者进行评估,其中10名是年龄在30至40岁之间的接受抗逆转录病毒治疗的AIDS患者。患者患有各种病理学的口腔炎性病变:
12名口-咽粘膜炎患者;
4名患有口腔中口疮性损伤的患者;
4名出现创伤后损伤的患者;
3名口腔扁平苔藓患者;
3名患有放疗引起的口炎的患者;
3名出现口腔手术副作用的患者;
1名粘膜白斑病患者。
将15ml小药袋中的实施例1的组合物用水按1∶4的比例进行稀释并用其对患者进行治疗。将该微粘的溶液在口中保留2-3分钟,在此期间,用其漱口并使其在口中打漩以使其在口腔粘膜的整个表面上均匀分布。然后将该溶液弃去。
该制剂在饭前60分钟使用,每天使用3次,连续使用七天。
在治疗结束时评估炎症和损伤的程度、对固体和半固体食物以及液体的吞咽困难的降低或消失以及该产品作用的持续时间。
在第一次给药后,已经有80%以上的患者在几小时之内感觉到疼痛减轻,从而可以进食。该作用持续三或四个小时。
在治疗3-4天后,约60%的被治疗个体的口腔粘膜损伤已经被治愈。在治疗结束时,该百分比达到了90%。在剩余的三个病例中仅仅有病理学情况的持续,但是与治疗开始时相比,该症状得到了改善,至少显著改善了生活质量,并且恢复了正常的、多种多样的饮食。
实施例3
两名咽喉疼痛(咽喉痛)的患者用止痛剂或其它局部药物不能得到缓解。将15ml小药袋中的实施例1的组合物用水以1∶4的比例进行稀释,然后用其对患者进行处理。将该溶液在口腔中保持约一分钟,在此期间,用其漱口以使其与咽喉组织进行良好的接触。然后将该溶液弃去。在十分钟内,患者的咽喉痛症状得到了显著的改善,这种缓解作用可持续数小时。

Claims (7)

1、一种用于治疗口腔粘膜炎症的药物组合物,该组合物基于组合物总重量计含有0.01-5%的透明质酸、0.01-3%甘草次酸和1-20%聚乙烯吡咯烷酮作为活性成分,这些活性成分与适于局部给药的赋形剂和辅剂相混合。
2、如权利要求1所述的组合物,其中所述赋形剂和辅剂选自增粘剂、表面活性剂、稳定剂-防腐剂、矫味剂、芳香剂、甜味剂、生物粘附剂和共溶剂。
3、如权利要求1所述的组合物,其中所述赋形剂和辅剂选自纤维素衍生物、丙烯酸或甲基丙烯酸聚合物或共聚物、乙二醇或丙二醇、聚乙氧基化氢化蓖麻油、EDTA、苯甲酸钠、山梨酸钠或山梨酸钾、糊精、糖精钠和阿司帕坦。
4、如权利要求1-3中任一项所述的组合物,其中含有抗菌剂/消毒剂、杀真菌剂、止痛剂、抗炎剂、柔润剂和局部麻醉剂中的至少一种。
5、如权利要求1所述的组合物,其具有如下百分比组成:
透明质酸钠                         0.1
甘草次酸                           0.06
PVP                                9.0
麦芽糖糊精                         6.00
丙二醇                             2.94
山梨酸钾                           0.3
苯甲酸钠                           0.3
羟乙基纤维素                       1.5
氢化蓖麻油PEG-40                   0.27
EDTA二钠                           0.1
苯扎氯铵                           0.5
香料                               0.16
糖精钠                             0.1
净化水                                 78.44。
6、透明质酸、甘草次酸和聚乙烯吡咯烷酮在制备用于治疗口腔粘膜炎症的药物中的应用。
7、权利要求6的应用,其中所述口腔粘膜炎症是粘膜炎或口炎。
CNB018134386A 2000-07-28 2001-07-18 用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物 Expired - Lifetime CN1198625C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI001732A IT1318649B1 (it) 2000-07-28 2000-07-28 Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ITMI2000A001732 2000-07-28

Publications (2)

Publication Number Publication Date
CN1474700A CN1474700A (zh) 2004-02-11
CN1198625C true CN1198625C (zh) 2005-04-27

Family

ID=11445589

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018134386A Expired - Lifetime CN1198625C (zh) 2000-07-28 2001-07-18 用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物

Country Status (26)

Country Link
US (1) US20020173485A1 (zh)
EP (1) EP1313489B1 (zh)
JP (1) JP2004505028A (zh)
KR (1) KR100761051B1 (zh)
CN (1) CN1198625C (zh)
AR (1) AR030068A1 (zh)
AT (1) ATE289512T1 (zh)
AU (2) AU2002212113B2 (zh)
BR (1) BRPI0112962B8 (zh)
CA (1) CA2424346C (zh)
CZ (1) CZ301461B6 (zh)
DE (1) DE60109044T2 (zh)
ES (1) ES2236324T3 (zh)
HK (1) HK1059215A1 (zh)
HR (1) HRP20030046B1 (zh)
IT (1) IT1318649B1 (zh)
MX (1) MXPA03000712A (zh)
MY (1) MY130477A (zh)
NO (1) NO329574B1 (zh)
NZ (1) NZ523832A (zh)
PL (1) PL204397B1 (zh)
PT (1) PT1313489E (zh)
RU (1) RU2272636C2 (zh)
UA (1) UA79075C2 (zh)
WO (1) WO2002009637A2 (zh)
ZA (1) ZA200300712B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109328058A (zh) * 2016-07-27 2019-02-12 株式会社利他药业 口腔粘膜贴附材料及其制造方法

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547433B2 (en) 2001-02-15 2009-06-16 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20050142208A1 (en) 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
WO2004064850A1 (en) * 2003-01-23 2004-08-05 Ml Laboratories Plc Antiviral composition comprising a sulphated glucose polymer and a bacteriostatic agent
GB0312485D0 (en) * 2003-05-30 2003-07-09 Dodson & Horrell Horse food composition
ITMI20031291A1 (it) 2003-06-25 2004-12-26 Ricerfarma Srl Uso di acido ialuronico per la preparazione di composizioni per il trattamento di afte del cavo orale.
WO2005027939A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008027904A2 (en) * 2006-08-28 2008-03-06 Rexaderm, Inc. Dry wound dressing and drug delivery system
KR100758636B1 (ko) * 2006-12-19 2007-09-13 고려대학교 산학협력단 생체 점막 점착성 고분자 접합체 및 이의 제조방법
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
ES2729925T3 (es) 2007-11-13 2019-11-07 Meritage Pharma Inc Composiciones de corticosteroides
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
GB0813589D0 (en) * 2008-07-24 2008-09-03 Sinclair Pharmaceuticals Ltd Composition
PT2435021E (pt) * 2009-05-25 2013-09-30 Sofar Swiss Sa Utilização de uma combinação fixa de glicosaminoglicano e composição mastigável compreendendo a referida combinação fixa
RU2587570C2 (ru) 2010-04-14 2016-06-20 Алтрия Клаинт Сервисиз Инк. Отформованный бездымный табачный продукт
RU2552936C2 (ru) 2010-11-12 2015-06-10 Колгейт-Палмолив Компани Продукт для ухода за полостью рта и способы его применения и получения
ES2388281B1 (es) 2010-12-27 2013-10-01 Laboratorios Viñas S.A. Composición farmacéutica que comprende ácido hialurónico y un compuesto de zinc y pastilla con palito y procedimiento para preparación correspondientes
ITMI20110954A1 (it) * 2011-05-26 2012-11-27 Professional Dietetics Srl Combinazioni per il trattamento delle mucositi vaginali o rettali
US10799548B2 (en) * 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
CA2964064C (en) 2013-10-16 2022-07-05 Orahealth Corporation Treating mucosal lesions with hyaluronan delivered from an adhering troche
CN105342987A (zh) * 2015-12-04 2016-02-24 亚飞(上海)生物医药科技有限公司 一种凝胶及其制备方法和应用
ITUA20161822A1 (it) * 2016-03-18 2017-09-18 Indena Spa Composizioni utili nella prevenzione e/o nel trattamento di patologie del cavo orale, delle prime vie aeree e dell’esofago
IT201600079773A1 (it) * 2016-07-29 2018-01-29 Matteo Bevilacqua Composizioni contenenti oligosaccaridi di acido ialuronico (HA4), condroitin solfato (CS2-4) ed eparan solfato (HS2-4), triterpeni pentaciclici e derivati per uso medico curativo e metodo per la preparazione di tali composizioni.
CN106176863A (zh) * 2016-08-04 2016-12-07 陈广圣 一种医用抗菌剂
CN107802641A (zh) * 2016-09-09 2018-03-16 李明典 口腔软组织(牙龈、粘膜)抗发炎酸痛剂
EP3459368A1 (en) * 2017-09-20 2019-03-27 Geophyt S.r.L. Food integrator for antineoplastic therapies
CN109331023A (zh) * 2018-11-12 2019-02-15 沈阳药科大学 甘草次酸的医药用途
KR102475125B1 (ko) 2019-08-07 2022-12-07 고려대학교 산학협력단 일산화질소 복합체를 포함하는 구강 점막염 치료용 조성물 및 구강 점막염 치료제
IT202100011879A1 (it) * 2021-05-10 2022-11-10 Aurora Biofarma S R L Composizione orale per il trattamento delle esofagiti

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA82361B (en) * 1981-02-06 1982-12-29 Biorex Laboratories Ltd Pharmaceutical composition for treating diseases of the oral cavity
GB2092442B (en) * 1981-02-06 1984-02-08 Biorex Laboratories Ltd Pharmaceutical composition for treating diseases of the oral cavity containing glycyrrhetinic acid or a derivative thereof
JPS6117510A (ja) * 1984-07-03 1986-01-25 Toyobo Co Ltd 口腔粘膜適用徐放性ニフエジピン製剤
JPS6440423A (en) * 1987-08-05 1989-02-10 Kyukyu Yakuhin Kogyo Kk Patch for mucosa in oral cavity
US4965253A (en) * 1987-10-14 1990-10-23 University Of Florida Viscoelastic material for ophthalmic surgery
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
JPH09169652A (ja) * 1995-12-18 1997-06-30 Lion Corp 水性液状組成物
JPH10182390A (ja) * 1996-12-25 1998-07-07 Lion Corp 口腔用組成物
JP2000178185A (ja) * 1998-12-18 2000-06-27 Lion Corp 口腔粘膜付着型徐放性錠剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109328058A (zh) * 2016-07-27 2019-02-12 株式会社利他药业 口腔粘膜贴附材料及其制造方法

Also Published As

Publication number Publication date
HK1059215A1 (en) 2004-06-25
CA2424346C (en) 2010-03-09
NZ523832A (en) 2003-09-26
MXPA03000712A (es) 2004-11-01
BR0112962B1 (pt) 2013-12-31
MY130477A (en) 2007-06-29
WO2002009637A3 (en) 2002-12-05
HRP20030046A2 (en) 2004-04-30
HRP20030046B1 (en) 2011-08-31
NO20030411D0 (no) 2003-01-27
CN1474700A (zh) 2004-02-11
DE60109044T2 (de) 2005-07-21
IT1318649B1 (it) 2003-08-27
ATE289512T1 (de) 2005-03-15
PL204397B1 (pl) 2010-01-29
BRPI0112962B8 (pt) 2021-05-25
CA2424346A1 (en) 2002-02-07
ITMI20001732A0 (it) 2000-07-28
EP1313489B1 (en) 2005-02-23
AU1211302A (en) 2002-02-13
ITMI20001732A1 (it) 2002-01-28
PL362921A1 (en) 2004-11-02
AU2002212113B2 (en) 2006-01-12
DE60109044D1 (de) 2005-03-31
KR20030069979A (ko) 2003-08-27
US20020173485A1 (en) 2002-11-21
KR100761051B1 (ko) 2007-10-04
UA79075C2 (uk) 2007-05-25
NO20030411L (no) 2003-01-27
BR0112962A (pt) 2003-06-24
EP1313489A2 (en) 2003-05-28
PT1313489E (pt) 2005-05-31
RU2272636C2 (ru) 2006-03-27
ES2236324T3 (es) 2005-07-16
ZA200300712B (en) 2004-02-09
JP2004505028A (ja) 2004-02-19
NO329574B1 (no) 2010-11-15
CZ301461B6 (cs) 2010-03-10
AR030068A1 (es) 2003-08-13
WO2002009637A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
CN1198625C (zh) 用于治疗粘膜炎、口炎和贝赫切特综合征的药物组合物
EP1997478B1 (en) Liquid formulations for the prevention and treatment of mucosal diseases and disorders
AU2002212113A1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
US6828308B2 (en) Compositions and methods for the treatment or prevention of inflammation
WO2019155389A1 (en) An aqueous mucoadhesive and bioadhesive composition for the treatment
EP0380367A1 (en) Compositions and method for the treatment of disease
HU228669B1 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
CN1226037C (zh) 硫糖铝在制备治疗宫颈糜烂药物上的用途
CN1903289A (zh) 治疗痔类肛肠疾病的凝胶剂及制备方法
CA2385974A1 (en) Treating endometriosis or infertility or improving fertility
RU2741593C2 (ru) Средство для применения при воспалительных состояниях слизистых оболочек
CA2434608C (fr) Favorisation de la reconstruction cellulaire et/ou de la differenciation cellulaire avec sucre non metabolisable et un absorbant polymerique
WO2003022292A1 (fr) Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation
CN114828838B (zh) 粘膜或皮肤中的炎性病况的治疗
CN1244398A (zh) 中、西药结合治疗皮肤真菌病症的改进型酊剂
JPH07267867A (ja) 抗内毒素作用を有する治療用薬剤
TWI252103B (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and Behcet's syndrome
BRPI0902144A2 (pt) processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam
CN118845615A (zh) 一种治疗骨关节炎的透皮给药制剂及其制备方法
CN114828838A (zh) 粘膜或皮肤中的炎性病况的治疗
CZ307436B6 (cs) Farmaceutický prostředek s virucidním a antibakteriálním účinkem
CN115025076A (zh) 利多卡因或其药学上可接受的盐在制备用于溃疡性结肠炎灌肠治疗的药物组合物中的用途
CZ27946U1 (cs) Farmaceutický prostředek s virucidním a antibakteriálním účinkem
WO2016015691A1 (en) A pharmaceutical composition having antibacterial and virucidal effects
AU2004222773A1 (en) A method for treatment of mouth lesions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059215

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170502

Address after: Wiltshire

Patentee after: United Pharmaceutical Co Ltd

Address before: British Godel Ming

Patentee before: Sinclair Pharmaceuticals Ltd.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050427